Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Olema Pharmaceuticals (OLMA) Profit After Tax (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Profit After Tax data on record, last reported at -$53.1 million in Q1 2026.

  • On a quarterly basis, Profit After Tax fell 74.7% to -$53.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$185.2 million, a 43.65% decrease, with the full-year FY2025 number at -$162.5 million, down 25.47% from a year prior.
  • Profit After Tax reached -$53.1 million in Q1 2026 per OLMA's latest filing, down from -$46.1 million in the prior quarter.
  • Over the last five years, Profit After Tax for OLMA hit a ceiling of -$20.1 million in Q2 2023 and a floor of -$53.1 million in Q1 2026.
  • A 5-year average of -$32.1 million and a median of -$30.4 million in 2025 define the central range for Profit After Tax.
  • Peak YoY movement for Profit After Tax: crashed 100.28% in 2022, then soared 38.84% in 2023.
  • Tracing OLMA's Profit After Tax over 5 years: stood at -$26.2 million in 2022, then dropped by 2.27% to -$26.8 million in 2023, then dropped by 25.38% to -$33.6 million in 2024, then crashed by 37.22% to -$46.1 million in 2025, then decreased by 15.26% to -$53.1 million in 2026.
  • Business Quant data shows Profit After Tax for OLMA at -$53.1 million in Q1 2026, -$46.1 million in Q4 2025, and -$42.2 million in Q3 2025.